Shares of LogicBio Therapeutics fell more than 57 percent on February 2 after the company announced that its gene therapy for pediatric patients with methylmalonic acidemia was placed on clinical hold by the U.S. Food and Drug Administration.
Shares of Taysha Gene Therapies were down more than 10 percent after a patient’s death marred positive interim data for the company’s experimental gene therapy treatment for Sandhoff and Tay-Sachs diseases, which are two forms of GM2 gangliosidosis.
Pfizer Inc. said on January 21 the U.S. health regulator declined to approve somatrogon as a treatment for growth hormone deficiency in children that the company developed with partner Opko Health Inc.
The U.S. government’s Medicare program on January 11 said it plans to cover Alzheimer’s treatments including Biogen Inc.’s Aduhelm, with some conditions.
Palo Alto, Calif.-based BridgeBio Pharma reported topline data from Part A (Month 12) of the company’s Phase III ATTRibute-CM study of acoramidis for symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM). The drug failed the study arm.
Valneva’s share price jumped more than 20 percent on November 10 after the French vaccines company won European Commission approval for a deal under which it would supply up to 60 million doses of the COVID-19 vaccine candidate VLA2001 over two years.
For the past 20 years, Novartis has held a 33 percent stake in Roche, the company’s Basel, Switzerland neighbor. Now, Novartis has divested the Swiss drugmaker’s one-third stake to Roche for $20.7 billion.
Moderna Inc. on Nov. 4 slashed the 2021 sales forecast for the company’s Covid-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand, sending its shares tumbling 16 percent.
Shares of Novavax Inc. fell 16 percent after a report from Politico said the company faces significant hurdles in proving it can manufacture the experimental Covid-19 vaccine NVX-CoV2373 that meets regulators’ quality standards, resulting in production delays.
Atea Pharmaceuticals Inc.’s experimental Covid-19 antiviral pill being developed with Roche failed to help patients with mild and moderate Covid-19 in a small study of mostly low-risk patients, driving the Boston-based drugmaker’s shares down more than 65 percent on Oct. 19.
